Literature DB >> 22700846

Variability of sputum inflammatory mediators in COPD and α1-antitrypsin deficiency.

Helen Stone1, Gillian McNab, Alice M Wood, Robert A Stockley, Elizabeth Sapey.   

Abstract

There is inherent daily variability of sputum inflammatory mediators in stable-state patients with usual chronic obstructive pulmonary disease (COPD). The variability of pulmonary inflammation in patients with α(1)-antitrypsin deficiency (A1ATD) is unknown. Our study aimed to quantify this variability, in comparison to patients with usual COPD, in order to facilitate power calculations for proof of concept trials of putative specific anti-inflammatory agents in both groups. Sputum interleukin (IL)-8, myeloperoxidase (MPO), leukotriene B(4) (LTB(4)) and differential cell counts were measured in 12 usual COPD patients and 12 A1ATD patients on nine occasions over a 1-month period. All samples were obtained in the stable clinical state. There was significant daily variability in all mediators in all patients. A1ATD patients had higher sputum concentrations of IL-8 and LTB(4) compared with usual COPD, but lower levels of MPO and absolute neutrophil counts. Patients with usual COPD had more intra-patient variability, A1ATD patients demonstrated greater inter-patient variability. There are increased concentrations of pulmonary inflammatory mediators but fewer sputum neutrophils in A1ATD compared with usual COPD. The daily variability of inflammatory mediators and cell counts was significantly reduced in both groups by averaging sequential samples. This can be utilised to perform power calculations for future proof of concept studies; averaging three sequential samples appears optimum.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22700846     DOI: 10.1183/09031936.00162811

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  21 in total

Review 1.  Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?

Authors:  Diana Crossley; Robert Stockley; Elizabeth Sapey
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

2.  Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.

Authors:  Adam Wanner; Stephen C Groft; J Russell Teagarden; Jeffrey Krischer; Barry R Davis; Christopher S Coffey; David H Hickam; Jeffrey Teckman; David R Nelson; Michael L McCaleb; Rohit Loomba; Charlie Strange; Robert A Sandhaus; Mark Brantly; Jonathan M Edelman; Albert Farrugia
Journal:  Chronic Obstr Pulm Dis       Date:  2015-04-28

3.  Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.

Authors:  Daniel J Smith; Paul R Ellis; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

Review 4.  Neutrophil Modulation in Alpha-1 Antitrypsin Deficiency.

Authors:  Elizabeth Sapey
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

5.  Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency.

Authors:  Derek W Russell; Amit Gaggar; George M Solomon
Journal:  Ann Am Thorac Soc       Date:  2016-04

6.  Pulmonary Infections in the Elderly Lead to Impaired Neutrophil Targeting, Which Is Improved by Simvastatin.

Authors:  Elizabeth Sapey; Jaimin M Patel; Hannah L Greenwood; Georgia M Walton; Jon Hazeldine; Charendeep Sadhra; Dhruv Parekh; Rachel C A Dancer; Peter Nightingale; Janet M Lord; David R Thickett
Journal:  Am J Respir Crit Care Med       Date:  2017-11-15       Impact factor: 21.405

7.  Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.

Authors:  Janine Koepke; Marc Dresel; Severin Schmid; Timm Greulich; Björn Beutel; Bernd Schmeck; Claus Franz Vogelmeier; Sabina Janciauskiene; Andreas Rembert Koczulla
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

8.  Longer telomere length in COPD patients with α1-antitrypsin deficiency independent of lung function.

Authors:  Aabida Saferali; Jee Lee; Don D Sin; Farshid N Rouhani; Mark L Brantly; Andrew J Sandford
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

9.  Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients 'on' or 'off' augmentation therapy.

Authors:  I Mark Olfert; Moh H Malek; Tomas M L Eagan; Harrieth Wagner; Peter D Wagner
Journal:  BMC Pulm Med       Date:  2014-06-30       Impact factor: 3.317

10.  Sputum myeloperoxidase in chronic obstructive pulmonary disease.

Authors:  Alling Zhu; Dehai Ge; Jingying Zhang; Yue Teng; Cheng Yuan; Mao Huang; Ian M Adcock; Peter J Barnes; Xin Yao
Journal:  Eur J Med Res       Date:  2014-03-03       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.